Could Low-Dose Naltrexone be an Effective Treatment for Hailey-Hailey Disease?

  • Denisse Izquierdo Rare Genomics Institute, Hanover, MD
  • Benoît Renvoisé Rare Genomics Institute, Hanover, MD
  • Kathleen LaPoint Rare Genomics Institute, Hanover, MD
  • Arvin M Gouw Rare Genomics Institute, Hanover, MD
  • Jimmy Ch Lin Rare Genomics Institute, Hanover, MD
  • Imran Babar Rare Genomics Institute, Hanover, MD

Abstract

Although originally described by the Hailey brothers in 1939, Hailey-Hailey disease (HHD), or familial benign chronic pemphigus, still does not have an established treatment method. Recent testimonial and anecdotal evidence suggest low-dose naltrexone (LDN) as an effective treatment for HHD. Naltrexone was originally approved by the US Food and Drug Administration in 1984 for the treatment of alcohol and opiate addiction. In lower doses (4.5 mg or less rather than 50 mg), naltrexone is being used to treat many diseases; however, there are no published studies on its long-term efficacy or for the treatment of HHD.

Published
2016-07-19
Section
Mini Review